IPATential150 : A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

This phase III trial is trying to determine the effect of adding an investigational drug (Ipatasertib) to treatment with two other drugs (Abiraterone and Prednisone/Prednisolone) in patients with metastatic Castration-Resistant Prostate Cancer (mCRPC).
 

This trial is treating patients with Prostate Cancer.

This is a systemic therapy trial.

You may be able to join this trial if:

• You are able to swallow medication by mouth.
• You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
• Your cancer has spread to other parts of the body.

You may be excluded from this trial if:

• You have a certain disease or psychological condition.
• You have been diagnosed with a prior or secondary type of cancer.
• You have had certain treatments, surgical procedures or drugs.
• You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.